GlassScriptPhysician profile
Logan S Jester
NPI 1710646880
$6,062.26
in general payments reported to CMS, 2019-2025
34 companies · $18.14 in 2025
The $18.14 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,141 · 2023: $2,386 · 2024: $1,517 · 2025: $18.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,872 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,871.69 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,018.22 | 2022-2024 | |
| Novo Nordisk INC | $985.91 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $898.38 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $611.23 | 2022-2024 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $503.47 | 2022-2024 | |
| Pfizer INC. | $257.24 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $211.66 | 2022-2023 | |
| Glaxosmithkline, LLC. | $190.19 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $152.66 | 2022 | |
| Paratek Pharmaceuticals, INC. | $148.72 | 2022-2024 | Nuzyra |
| Exact Sciences Corporation | $135.83 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.42 | 2022-2024 | Jardiance |
| Idorsia Pharmaceuticals US INC | $103.18 | 2022-2023 | Quviviq |
| Amgen INC. | $84.17 | 2023-2024 | Otezla, Repatha |
| Currax Pharmaceuticals LLC | $79.64 | 2023 | Nexletol, Contrave, Nexlizet |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $68.21 | 2024-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.06 | 2023-2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $52.07 | 2023-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $45.55 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.97 | 2022-2023 | |
| Nevro Corp. | $35.43 | 2023 | Senza |
| Phathom Pharmaceuticals, INC. | $34.58 | 2023-2024 | Voquezna |
| Merck Sharp & Dohme LLC | $28.23 | 2022-2023 | Belsomra, Steglatro |
| Medline Industries LP | $27.73 | 2023-2024 | |
| Philips North America LLC | $22.66 | 2024 | (Ck7) Extended Holter |
| Hologic Sales and Service, LLC | $18.99 | 2022 | |
| Boston Scientific Corporation | $18.20 | 2022 | |
| Upsher-Smith Laboratories LLC | $18.02 | 2022 | |
| Mycovia Pharmaceuticals, INC. | $16.14 | 2023 | Vivjoa |
| Novartis Pharmaceuticals Corporation | $15.36 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.85 | 2022 | |
| Astellas Pharma US INC | $14.58 | 2022 | |
| Watermark Medical, INC. | $13.57 | 2024 | |
| Horizon Therapeutics Plc | $13.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Logan Jester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.